Business Wire

DNA Script Enables Same-day q/dPCR from Design to Results with Launch of Next-generation SYNTAX Kits at AGBT

6.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours. This announcement comes two days ahead of their AGBT presentation on Wed, June 8, at 2:55pm EDT, where their founders will review recent data showcasing the new applications enabled for the SYNTAX System.

For the first time since the introduction of PCR in 1984, labs will be able to design and print q/dPCR assays, directly on their benchtops, in as little as 8 hours. The combination of increased performance, just 15 minutes of set up, rapid synthesis turnaround and complete workflow control provides labs the best value for custom modified oligos. The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.

“We see this product launch as a game-changer, enabling SYNTAX customers to be done with their assays before others have even started. More than ever before, science and innovation are in a race for results, whether it is an upcoming scientific publication, a new diagnostic test or even a vaccine. Researchers need to get there faster, and we will help them to get there first,” said DNA Script CEO and co-founder Thomas Ybert, Ph.D. “With an in-house, benchtop SYNTAX System and these new kits, we are enabling our customers to replace a complex synthesis workflow with a single instrument that takes the iterative assay development process from months down to days.”

This latest generation of kits launches several new capabilities on the SYNTAX Platform:

  • Print oligos up to 80 nt in length
  • Synthesize hydrolysis probes and primers in the same run, in as little as 8 hours
  • Print oligos at a higher yield and concentration (≥7 µM and ≥600 pmol)
  • Label probes with fluorophores, quenchers and biotin

DNA Script’s SYNTAX Platform offers researchers dramatic time savings, printing primers and probes in 8 - 12 hours, as well as the best value per assay compared to leading third-party oligo service solutions in the marketplace. Early adopters of the SYNTAX platform have already leveraged on-demand synthesis to eliminate bottlenecks in the development of assays for biothreat detection, assays for rapid-response to viral outbreaks, and novel vaccines and therapies.

“The SYNTAX System is a game changer for preclinical CRO labs like ours. For the biomarker identification and gene expression profiling we do, we spend thousands of dollars a month on primers and probes and end up waiting for them to be synthesized and shipped. Having SYNTAX on site cuts our assay turnaround time, decreases our cost per assay by ~30%, and enables our lab to optimize expression assays more quickly--all of which significantly improves our bottom line," said Jonathan Wray, Managing Partner at DC3 Therapeutics. “The ease of use and excellent service and support from DNA Script enabled us to be up and running with the SYNTAX System in no time.”

As a Bronze sponsor, DNA Script is hosting a hospitality room in the Jade-Lexington Suite throughout the duration of the AGBT Conference, where attendees can see the SYNTAX System in action, demonstrating the speed of synthesizing probes and primers in-house with plug-and-play ease and automation. One-on-one demonstrations can be scheduled in advance.

DNA Script presentations at AGBT include:

  • Podium Presentation: Same-Day Enzymatic DNA Synthesis: Now Print Primers and Labeled Probes Using the SYNTAX System
    Presenters: Ybert and DNA Script CTO and co-founder Xavier Godron, Ph.D.
    Date & Time: Wed, June 8, 2:55 - 3:15 pm EDT
    Location: Main Session - Floridian Salons A-L
  • Poster Presentation (#517): Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants
    Presenters: Benoit Derrien, Ph.D., Application Project Leader, DNA Script
    Date & Time: Tues, June 7, 1:30 - 3:00 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII
  • Poster Presentation (#540): Access to Synthetic Oligos Produced by Enzymatic DNA Synthesis (EDS) Accelerated the Development of Candida glabrata Mutants During the COVID-19 Pandemic
    Presenters: Colin Clairet, Ph.D., Post-doctoral Researcher, Institut Pasteur
    Date & Time: Wed, June 8, 4:40 pm - 6:10 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII

“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX Platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Ybert. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of the 21st century.”

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts in the US
Seismic

Valerie Enes
415-692-6799
valerie@teamseismic.com

DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co

Press contact in Europe
ALIZE RP

Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 20:16:00 EEST | Press release

Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 19:16:00 EEST | Press release

Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure controlsoftware to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers. The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses. The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly fas

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 11:52:00 EEST | Press release

SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 08:10:00 EEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye